Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
暂无分享,去创建一个
M. Guida | A. Paccagnella | V. Chiarion-Sileni | B. Silvestri | M. Michiara | P. Del Bianco | R. Ridolfi | A. Romanini | G. D. De Salvo | M. Dalla Palma | E. Naglieri